Skip to main content

Table 5 LncRNAs and miRNAs targeting for NPC therapeutic

From: Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect

LncRNAs/miRNAs

Potential therapeutic approaches

Anti-tumor effect

Source

miR-7

Upregulated by Curcumin

Triggered cell cycle arrest and apoptosis, retarded cell proliferation, migration and invasion by inhibiting Skp2

[196]

miR17-5p

Downregulation

Suppressed tumour proliferation via regulation of p21 protein

[197, 198]

miR-20a-5p

Downregulation

Enhance radiosensitivity via regulation of neuronal PAS domain protein 2 (NPAS2) gene

[199]

miR-26b

Upregulation

Enhance chemosensitivity (Cisplatin) by inhibiting JAG1 expression

[200]

miR29-c

Upregulated by knockdown of lncRNA X inactive-specific transcript (XIST) or HMG-box transcription factor 1 (HBP1)

Suppressed cell proliferation and enhance radiosensitive via reduce level of cyclin D1 and cyclin D3

[201, 202]

miR-93

Downregulation

Suppressed tumour growth and migration

[203]

miR-101

Upregulation

Suppressed metastasis and angiogenesis by negative regulation of integrin subunit alpha 3 (ITGA3) or Stathmin 1 (STMN1)

[190, 204]

miR-148b

Upregulation

Suppressed invasion, and metastasis by inhibiting metastasis-related gene 2 (MTA2)

[205]

miR-149

Downregulation

Suppressed proliferation, invasion and metastasis via the upregulation of plakophilin3 (PKP3) expression

[187]

miR-150

Upregulation

Suppressed cell proliferation and G1/S transition by targeting CCND1, CCND2, CDK2 and CCNE2

[206]

miR-185-3p

Upregulation

Enhance radiosensitivity through inhibition of mothers against decapentaplegic homolog 7 (SMAD7)

[207]

miR-205

Downregulation

Suppressed tumour growth and migration

[203]

miR-212

Upregulation

Suppressed invasion and migration by targeting SRY-Box Transcription Factor 4 (SOX4)

[208]

miR-324-3p

Upregulation

Suppressed invasion, cell proliferation, apoptosis by negative regulation of GLI Family Zinc Finger 3 (GLI3) gene

[209]

miR-422a

Upregulation

Suppressed EMT and metastasis by targeting FOXQ1

[186]

miR-432

Upregulation

Suppressed invasion and migration by regulation E2F transcription factor 3 (E2F3) expression

[210]

miR-504

Downregulation

Enhance radiosensitivity via upregulation of NRF1

[185]

LncRN UCA1

Downregulation

Suppressed invasion and cell proliferation via miR-145/A disintegrin and metalloprotease 17 (ADAM17) axis

[188]

LncRN CASC9

Downregulation

Suppressed the cancer progression by destabilising the HIF1α

[189]

LncRN AFAP1-AS1

Downregulation

Prevent to be co-expressed with PD-1 to promote immune escape

[211]

LncRN MEG3

Upregulation

Induced cell cycle arrest, inhibited cell proliferation and colony formation

[192]

LncRN PVT1

Downregulation

Enhance radiosensitivity via regulation of DNA damage repair pathway

[191]

LncRN ANCR

Downregulation

Enhance radiosensitivity via regulation of PTEN expression

[183]

LncRN MALAT1

Downregulation

Enhance radiosensitivity via regulation of miR-1/slug axis

[184]

LncRN NEAT1

Downregulation

Suppressed tumourigenesis and enhance chmeosensitivity (cisplatin) via regulation of miR-124 and Rsf-1/Ras-MAPK/let-7a-5p axis

[182]

LncRNA LINC00460

Downregulation

Suppressed EMT via regulation of miR-30a-3p/Ras-related protein 1A (Rap1A) axis

[212]

LncRNA NKILA

Upregulation

Suppressed carcinogenesis through the inhibition of NF-κB signalling

[213]

LncRNA FAM225A

Downregulation

Suppressed cell proliferation and invasion by regulation of ITGB3 and FAK/PI3K/Akt pathways

[194]

LncRNA DRAIC

Downregulation

Suppressed invasion and migration by miR-122/SATB1 axis

[214]

LncRNA TP73-AS1

Downregulation

Suppressed migration and invasion via regulation of miR-495/JAM-A axis

[215]

LncRNA FOXD3-AS1

Downregulation

Suppressed colony formation, invasion and migration via regulation of miR-185-3p/FOXD3 axis

[195]

  1. AFAP1-AS actin fiber-associated protein 1-antisense RNA1, Akt serine/threonine kinase 2, ANCR antidifferentiation non-coding RNA, CASC9 cancer susceptibility candidate 9, CCND 1 or 2 cyclin D1 or 2, CCNE2 cyclin E2, CDK2 cyclin dependent kinase 2, DRAIC downregulated RNA in cancer, FAK focal adhesion kinase, FAM225A family with sequence similarity 225 member A, FOXD3 forkhead box protein D3, FOXD3-AS1 forkhead box protein D3-antisense RNA 1, FOXQ forkhead box protein Q1, ITGB3 integrin β3, JAG1 jagged 1, JAM-A junctional adhesion molecule-A, LINC00460 long intergenic non-protein coding RNA 460, LncRNA long non-coding RNA, NF-κB nuclear factor kappa B, MALAT1 metastasis associated lung adenocarcinoma transcript 1, MEG3 maternally expressed gene 3, NKILA NF-kappabeta-interacting long noncoding RNA, PD-1 programmed cell death 1, PI3K phosphoinositide 3-Kinase, PTEN phosphatase and tensin homolog, PVT1 plasmacytoma variant translocation 1, p21 cyclin-dependent kinase inhibitory protein-1, Ras-MAPK rat sacrcoma-mitogen-activated protein kinase, Rsf remodelling and spacing factor 1, SATB special AT-rich sequence-binding protein-1, Skp2 S-phase kinase-associated protein 2, slug zinc finger protein SNAI2, SRY-Box sex-determining region Y protein-Box, TP73-AS1 P73 antisense RNA 1T, UCA1 urothelial cancer associated 1